Mutations arising n viuvo in recorder genes ofhuman blood cells provide biomarkers for mlecular epidemiology by serving as surrogates for cancer-causing genetic changes. Current markers include mutations ofthe glycophorin-A (GPA) or hemoglobin (Hb) genes, nmasured in red blood cells, or mutations ofthe hypoxanthine-guanine phosphoribosyltransferase (hp,t) 
Introduction
Molecular epidemiology is an attempt to combine the disease relevance oftraditional epidemiology with the use of biomarkers to overcome limitations in studying diseases that are infrequent or have long incubation periods. Biomarkers measure the in vivo effects of deleterious environmental agents and may even serve as surrogates for disease. However, interpretation of human studies is dependent on the biomarker employed. Does it sensitively detect exposures? Is there any specificity? Does the biomarker detect only exposure or does it reveal in vivo toxic effects that, while not disease effects, help to predict them? Answers, of course, require an understanding of the biology of the biomarkers.
Some human cancers are undoubtedly caused, at least in part, by genotoxic carcinogens. Human exposures to these agents can be monitored by biomarkers of chromosome or gene level ' damage, or through direct assessments of DNA damage, chemical adduction, or repair. This review will consider a particular subset of these, i.e., gene level damage. Specifically, we will focus on the measurement and analysis of somatic cell gene mutations arising in vivo in human blood cells. Although all of the assays for human monitoring will be considered, the emphasis will be on in vivo hypoxanthine-guanine phosphoribosyltransferase (hprt) mutations in T-lymphocytes.
Cells Used for Studies of Current Biomarkers of in Vivo Somatic Cell Mutations in Humans
At present, mutations are scored as mutant cells in peripheral blood, i.e., red blood cells (RBCs) or T-lymphocytes (T-cells) (Table 1) . However, the mutations giving rise to these mutants arise in progenitor cells. For the RBC assays, mutations arise in multipotent stem cells or in somewhat differentiated hematopoietic precursor cells in the bone marrow. Continual proliferation and differentiation ofthese mutant progenitors produce the peripheral blood RBCs scored in the assays. For the T-cell assays, mutations in adults arise in differentiated, mature T-cells (1) , probably in lymph nodes or other body tissues. Although fully differentiated, these cells retain the capacity for limited (2) ]. For example, mutations arising in stem cells continuously produce mutant progeny. Therefore, a characteristic of stem cell mutations for human monitoring is memory, i.e., mutations arising in the distant past can be detected. Costs ofmemory, however, include variability, determined in part by the number of stem cells producing the population ofmature cells sampled at any given time, and loss of temporal relationships between induced mutational events and the detection ofmutants in peripheral blood. In contrast, mutations arising in differentiated T-cells are more closely related in time to the presence of mutant cells in the peripheral blood, especially ifthere is a finite life span ofmutants. The cost, of course, is memory.
Mature RBCs have lost their nucleus. There is, therefore, no possibility for molecular studies to define molecular spectra of mutations. The term "variants" acknowledges this. T-cells, however, can be propagated in vitro and studied at the molecular level. Also, the T-cell receptor (TcR) genes, which rearrange during thymic differentiation of individual T-cells, may be analyzed in these cells relative to mutations (1) . This allows decisions to be made regarding the in vivo independence ofdifferent mutant isolates and the differentiation stage in vivo when the mutation occurred.
There is probably metabolic competency for the target cells for both the hematopoietic and T-cell mutations. Hematopoietic precursor cells are surrounded by metabolically active macrophages in the bone marrow. Mature T-cells are partially metabolically competent and circulate through all ofthe tissues, where they are probably exposed to mutagenic metabolites. (Table 2 ). An understanding of the biology of each assay is important for its interpretation, especially for comparing results across assays. The mutational target sizes of the four genes studied in these assays differ. The Hb gene is 2 kb in length; however, the functional target size for the mutation currently scored isa single base change. The glycophorin A (GPA) and hprt genes are approximately equal in size; however, for GPA, the immunological methods used in the assay define target size by the antibody used and the protein structures required for recognition, whereas for hprt, chemical selection for mutants requires loss of catalytic activity of the HPRI enzyme, which may not occur following all possible mutations of the gene. For HLA, although this is, in principle, another large target gene, the immunological methods used for mutant detection make it difficult to define target size. Qualitative (Molecular) Aspects T-cells can be recovered from cloning assays and propagated in vitro into populations of sufficient size for molecular analyses. Although this has been accomplished for both hprt and HLA mutations, the largest database at present is for hprt.
hprt. There has been quite good aggreement among laboratories that approximately 15 % ofhprt mutations in normal adults result from gross structural alterations (2, (8) (9) (10) (11) . These include deletions, insertions, and rearrangements visible on Southern blots. The breakpoints ofthe alterations are distributed randomly within the gene, with no "hot spot" thus far identified (2) . Total deletions of hprt may show co-deletion of linked anonymous markers, which map several centiMorgans distant in both 5' and 3' directions, indicating that deletions can be quite large (12 Considering only the in vivo mutations (46 Lesch-Nyhan germinal, 51 normal adult somatic, 86 exposed adult somatic), several hotspots of mutation were observed. In particular, four basespair sites have been observed to be mutated in all groups. However, an additional 132 sites have been recorded with only a single observation per site. This suggests that there are many more sites inhprt that routinely mutate in viw (perhaps 100-200 additional sites), although the total number of in vivo mutations analyzed to date is not large enough to have observed them all.
HLA. Approximately 30% of the background mutations in adults result from total deletions of the gene as detected on Southern blots (14) . At HLA also, some deletions appear to be quite large, as demonstrated by the associated phenotypic loss of the HLA-B antigen coded by the allele in "cis" with the deleted HLA-A allele. Thus, deletions of > 1000 kb are seen. More importantly, recent molecular analyses of in vivo-derived HLA loss mutants show that approximately 30% also arise from mitotic recombination (15) . Therefore, this important class of mutations can be recognized at the molecular level. At (5, (16) (17) (18) . In fact, this increase was greater than 50% in smokers compared to nonsmokers in one study (16) . Other studies, however, have reported weaker or no effects (19, 20) . Smoking also results in somewhat higher GPA Vf values than for nonsmokers, but, in most studies, this increase does not achieve statistical significance (3). Preliminary results in ethylene oxide workers and ataxia telangiectasia and xeroderma pigmentosum heterozygotes suggest that in smokers the frequency of HbS variant cells is doubled as compared to nonsmokers (21).
Exposure to Cytotoxic Chemotherapeutic Agents
Most studies ofcancer patients undergoing chemotherapy have shown clear increases in hprtT-cell Mfvalues (22) (23) (24) . A similar increase has been seen for GPA mutations (25) . However, a recent study of 31 breast cancer patients receiving either chemotherapy, radiotherapy, or both reported no significant increase in hprt Mf attributable to chemotherapy (26) . The significant increases seen in treated patients could be accounted for solely by radiotherapy. Two of the agents received by these patients, cyclophosphamide and adriamycin have been implicated as mutagens in other studies of in vivo somatic mutation (25, 27) .
We have recently completed a similar study of women with breast cancer receiving potentially mutagenic therapies, and we obtained quite different results (20, 28) . All patients in our study had surgery with curative intent; subsequent therapy was in the adjuvant mode. Group 1 patients had no therapy beyond surgery, or had hormonal therapy, group 2 patients had local radiotherapy with or without hormonal therapy, and group 3 patients had chemotherapy with or without radiotherapy and/or hormones.
The first blood sample was obtained after surgery but before the onset ofadjuvant therapy; subsequent samples were obtained at 6-month intervals. Women presenting with noncancerous breast masses served as controls.
In contrast to the study noted above, there was a significant increase in mean Mfat 6 months in women receivingchemotherapy (18.2 ± 1.7 x 10-6) comparedtoprechemotherapy (11.1 ± 1.4 x 10-6). A more modest increase in mean post-treatment Mfwas seen after local radiotherapy, but neither this, nor (24, 27, (29) (30) (31) (32) . Induced mean frequencies in exposed individuals have varied from a low of7.5 x io-9 to a high of 5.5 x 10-6/cGy. This range of almost three orders of magnitude illustrates, in the extreme, the importance of timing in measuring in vivo-induced hprt mutations in peripheral blood T-cells. The rate of induction determined in servivors of the atomic bomb explosion is 7.5 x 10-' and was determined almost 45 years after the mutants were induced (32) . Eliminating this study reveals the range ofhprt mutant induction by ionizing radiation to be approximately 1-5 x 10-6/cGy for high-dose, low linear energy transfer irradiations.
The GPA assay was also used in studies of atomic bomb survivors 45 years after the event (33, 34) . These studies revealed an increment of approximately 0.4 x 10-6 induced GPA mutant RBCs/cGy, even at this late date, with a good deal of interindividual variability. Such results in RBCs are in accord with stem cell mutations, discussed above.
In an effort to better define the in vivo mutagenic effects of ionizing radiation, our laboratory has determined hprt Mfs in cancer patients exposed to an internal y-emitting radionuclide (131') (radioimmunotherapy [RT) producing total body irradiation in an exponentially decaying dose (35, 36) . We determined Mf values in 13 patients before and 36 patients after treatment. The post-treatment group included 11 samples obtained 2 months after a first treatment of62-104 cGy, 18 samples 2 months after the last of a series of multiple treatments (cumulative total of 128-669 cGy), and 7 samples obtained 10-48 months after the last of multiple treatments (cumulative total of 128-324 cGy). Based on either the dose of the first single treatment or the last of the multiple treatments, a dose-response relationship of 0.9-1.1 x 10-6 mutants/cCy was seen. Based on the total cumulative exposure, this induction feil to 0.2-0.3 x 10' in the 2-month samples, and to 0.09 x 10-6 in the 10-48-month samples. (This dose response compares with a value of 0.2 x 10-6 mutants/cGy in T-cells acutely irradiated in vitro.) These time-dependent declines in the in viw Mf point again to the bTotal independent mutations studied for the group.
importance of sampling time in human in vivo mutagenicity studies. Nonetheless, in vivo exposures to whole-body ionizing radiation clearly result in dose-dependent increases in hprt Mf.
Ionizing radiation is known to induce gross structural alterations in hprt and other recorder genes in cultured human and other mammalian cells. Bradley et al. (8) found an increased frequency of mutants with gross structual alterations on Southern blots in patients who had received radionuclides for diagnostic purposes (33%) as compared to patients before receiving radionuclides (13 %). In atomic bomb survivors, the frequencies of mutations showing gross structural alterations at hprt were essentially the same in individuals exposed to radiation from the bomb compared to nonexposed controls (9); however, as noted, the study was conducted almost 45 years after the exposure.
Our laboratory recently completed an analysis of241 independent in vivo hprt mutational events, isolated from 19 RIT patients (35, 36) . The hprt molecular lesions in these mutations were compared with the hprt molecular lesions in 118 in vivo mutations from 4 cancer patients before their therapy and in 287 background in vivo mutations in normal young males ( Table 3 ). The mutations from post-RIT patients showed clearly greater frequencies of gross structural alterations than those from pre-RIT or normal individuals. The latter two frequencies are quite similar, suggesting that cancer per se does not produce this sort of damage at hprt.
This difference in the kinds of in vivo hprt mutations after ionizing radiation, compared to in vivo mutations before exposure or in normals, extends to the sizes of the molecular lesions. Post-RIT patients have much higher frequencies of total gene deletions. Therefore, not only is the frequency of in vivo mutations with gross structural alterations increased after ionizing radiation exposures, the percentage oflesions with large deletions is increased. In individuals from whom 10 or more independent in vivo hprt mutations could be analyzed, the correlation between fraction of mutations with gross structural alterations and cumulative radiation dose was 0.79 (r = 0.82, r2 = 0.67 for the linear regression). Therefore, in our studies, 67 % of the variability in fraction of in vivo mutations with gross structual alterations could be explained by ionizing radiation exposure.
Taken in toto, the data for in vivo hprt T-cell mutations indicate that ionizing radiation produces deletions and that deletions, particularly large deletions, characterize the in vivo mutational spectrum for this sort of human mutagen exposure. There may also be a characteristic point mutational spectrum for in vivo hprt mutations resulting from ionizing radiation exposure. Sequence studies are in progress.
Occupational or Residential Mutagen Exposures
There are several published reports ofhuman monitoring, using the hprt cloning assay, for in vivo effects of occupational or residential chemical or radiation mutagen exposures (18, 19, (37) (38) (39) (40) (41) . For ionizing radiation, mutation induction appears to be more efficient for low-dose irradiations, being in the range of 10-induced mutants/cGy in some studies also (39) (40) (41) . Occupational exposures to chemical mutagens (e.g., chemotherapy nurses) resulted in elevations in Mf (18, 37) , but not when special precautions were taken (19) .
A recent, well-controlled study ofthe association between hprt Mfin peripheral blood T-cells and household radon concentrations deserves special mention (38) . A significant association was found between the log Mf and radon concentration. The doubling dose for Mf, estimated from two separate measurements ofhousehold radon concentrations, was 330 Bq/m3 and 210 Bq/m3, respectively. The authors caution that these data must be regarded as preliminary and that further, more extensive studies should be done. Molecular studies of these in vivo hprt mutations are clearly indicated.
Relevance of Mutation in Somatic Recorder Genes to Cancer
Several features of somatic cell gene mutation discovered thus far suggest that the recorder genes being studied serve as surrogates for cancer-causing mutations. First, considered in detail, is the finding that exposures to genotoxic carcinogens result in elevations in Mf (Vf) and, for ionizing radiation, result in a characteristic mutational spectrum. Also, two of the recorder genes being studied, GPA (16, 42, 43) . Molecular analyses of these fetal mutations show that they frequently arise in prethymic cells and that their mutational spectrum is characterized by specific deletions ofhprt exons 2 and 3, with deletion breakpoints giving rise to these deletions ocurring at a single site in intron 1 and at several sites in intron 3 (45) . The sites have in common all or an important portion of the consensus heptamer [CAC(T/A)GTG] for the VDJ recombinase that mediates cleavage ofthe TcR genes during thymic ontogeny (46) . Other hallmarks of a VDJ recombinase-mediated cleavage event characterize the junctional regions of the hprt deletions. Therefore, an illegitimate recombinase-mediated event can occur in the hprt gene which, when operative, accounts for 30% or more of the background mutations. A similar event has been shown to occur in a growth factor gene in 25 % of acute Tcell leukemias (47, 48) , where it may be pathogenic, and as an intermediate to several ofthe chromosomal translocations seen in B-cell lymphomas (49) . Thus, a mutagenic event that may be termed developmental mutagenesis has been uncovered by studies of in vivo hprt mutations in humans. Further studies should reveal its relevance to human cancer.
Conclusions
The status of in vivo somatic cell mutations as biomarkers for human studies has changed a good deal in recent years. Several markers of mutation are now available, and more are certain to come. Also, insights have been obtained that give a somewhat different picture than that derived from studies of in vitro mutations. These insights have provided an understanding of the biology ofthe different in vwvo mutagenicity assays in use. Results of human monitoring studies can now be interpreted in light of this biological understanding. The use ofthese assays in basic investigations of somatic cell mutation, and its role in human disease, is great.
The role of human in vivo somatic cell mutations as biomarkers for genotoxic carcinogen exposures is also being developed. Studies reviewed here indicate that mutations are induced by exposures to these agents and may be quite sensitive indicators of such exposures. The markers certainly are useful as population indicators of genotoxicity. Also, the ongoing molecular studies of in vivo-induced mutants may reveal characteristic mutational spectra that will allow "diagnosis" of specific deleterious agents. It may even be possible eventually to make individual health risk assessments following genotoxic exposures, although the potential for this is currently unexplored. A major goal in continuing studies ofin vivo somatic cell mutation in humans remains the development of methods for mutagenicity monitoring that will result in health benefits to the individuals studied.
